Stoke Therapeutics Balance Sheet
NASDAQ: STOKHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Stoke Therapeutics financial position
At the end of fiscal 2025, Stoke Therapeutics reported total assets of $418.4 million, up 54.1% from a year earlier against total liabilities of $66.0 million. Shareholders' equity stood at $352.5 million, or 84.2% of assets. The company held $84.2 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 5.28, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Stoke Therapeutics balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 84.22M | 127.98M | 191.44M | 113.56M | 144.90M | 287.31M | 222.47M | 105.40M |
| Short-Term Investments | 200.45M | 88.92M | 9.95M | 116.04M | 74.92M | 0 | — | — |
| Receivables | 5.94M | 1.67M | — | — | — | — | — | — |
| Total Current Assets | 305.70M | 232.76M | 215.34M | 244.07M | 229.22M | 293.93M | 226.03M | 106.14M |
| Property, Plant & Equipment | 3.15M | 3.91M | 5.82M | 6.67M | 4.14M | 2.67M | 2.51M | 1.19M |
| Long-Term Investments | 106.26M | 29.82M | — | — | — | — | — | — |
| Total Assets | 418.43M | 271.56M | 228.34M | 256.07M | 238.87M | 297.93M | 228.75M | 107.54M |
| Accounts Payable | 4.94M | 2.50M | 1.70M | 766.00K | 2.38M | 1.50M | 751.00K | 1.07M |
| Total Current Liabilities | 57.88M | 40.06M | 30.82M | 31.39M | 17.14M | 11.43M | 4.10M | 2.47M |
| Total Liabilities | 65.98M | 42.53M | 68.78M | 71.22M | 21.09M | 11.85M | 4.32M | 2.47M |
| Shareholders' Equity | 352.46M | 229.02M | 159.56M | 184.85M | 217.78M | 286.08M | 224.43M | 105.07M |
| Retained Earnings | -497.71M | -490.83M | -401.85M | -297.15M | -196.08M | -110.28M | -58.03M | -25.71M |
| Net Cash (Debt) | 284.67M | 216.90M | 201.39M | 229.59M | 219.81M | 287.31M | 222.47M | 105.40M |
| Shares Outstanding | 58.92M | 54.03M | 45.92M | 39.44M | 36.90M | 36.58M | 32.86M | 727.41K |
This table shows 8 annual periods of Stoke Therapeutics's balance sheet, from FY 2025 back to FY 2018, across 14 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow STOK's reporting calendar. What is a balance sheet?